O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells
- PMID: 16405512
- DOI: 10.1111/j.1471-4159.2005.03583.x
O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells
Abstract
Temozolomide (TMZ) is a methylating agent which prolongs survival when administered during and after radiotherapy in the first-line treatment of glioblastoma and which also has significant activity in recurrent disease. O6-methylguanine DNA methyltransferase (MGMT) is a DNA repair enzyme attributed a role in cancer cell resistance to O6-alkylating agent-based chemotherapy. Using a panel of 12 human glioma cell lines, we here defined the sensitivity to TMZ in acute cytotoxicity and clonogenic survival assays in relation to MGMT, mismatch repair and p53 status and its modulation by dexamethasone, irradiation and BCL-X(L). We found that the levels of MGMT expression were a major predictor of TMZ sensitivity in human glioma cells. MGMT activity and clonogenic survival after TMZ exposure are highly correlated (p < 0.0001, r2 = 0.92). In contrast, clonogenic survival after TMZ exposure does not correlate with the expression levels of the mismatch repair proteins mutS homologue 2, mutS homologue 6 or post-meiotic segregation increased 2. The MGMT inhibitor O6-benzylguanine sensitizes MGMT-positive glioma cells to TMZ whereas MGMT gene transfer into MGMT-negative cells confers protection. The antiapoptotic BCL-X(L) protein attenuates TMZ cytotoxicity in MGMT-negative LNT-229 but not in MGMT-positive LN-18 cells. Neither ionizing radiation (4 Gy) nor clinically relevant concentrations of dexamethasone modulate MGMT activity or TMZ sensitivity. Abrogation of p53 wild-type function strongly attenuates TMZ cytotoxicity. Conversely, p53 mimetic agents designed to stabilize the wild-type conformation of p53 sensitize glioma cells for TMZ cytotoxicity. Collectively, these results suggest that the determination of MGMT expression and p53 status will help to identify glioma patients who will or will not respond to TMZ.
Similar articles
-
Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT.Anticancer Res. 2009 Nov;29(11):4845-54. Anticancer Res. 2009. PMID: 20032445 Review.
-
[Treatment of glioma with temozolomide].Brain Nerve. 2009 Jul;61(7):849-54. Brain Nerve. 2009. PMID: 19618863 Review. Japanese.
-
The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity.Neuro Oncol. 2009 Feb;11(1):22-32. doi: 10.1215/15228517-2008-080. Epub 2008 Sep 23. Neuro Oncol. 2009. PMID: 18812520 Free PMC article.
-
Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine.Oncogene. 2007 Jan 11;26(2):186-97. doi: 10.1038/sj.onc.1209785. Epub 2006 Jul 3. Oncogene. 2007. PMID: 16819506
-
Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity.J Neurosurg. 2003 Mar;98(3):591-8. doi: 10.3171/jns.2003.98.3.0591. J Neurosurg. 2003. PMID: 12650433
Cited by
-
dCas9/CRISPR-based methylation of O-6-methylguanine-DNA methyltransferase enhances chemosensitivity to temozolomide in malignant glioma.J Neurooncol. 2024 Jan;166(1):129-142. doi: 10.1007/s11060-023-04531-z. Epub 2024 Jan 15. J Neurooncol. 2024. PMID: 38224404 Free PMC article.
-
Mammalian target of rapamycin inhibition protects glioma cells from temozolomide-induced cell death.Cell Death Discov. 2024 Jan 5;10(1):8. doi: 10.1038/s41420-023-01779-2. Cell Death Discov. 2024. PMID: 38182566 Free PMC article.
-
Targeting sphingolipid metabolism with the sphingosine kinase inhibitor SKI-II overcomes hypoxia-induced chemotherapy resistance in glioblastoma cells: effects on cell death, self-renewal, and invasion.BMC Cancer. 2023 Aug 16;23(1):762. doi: 10.1186/s12885-023-11271-w. BMC Cancer. 2023. PMID: 37587449 Free PMC article.
-
Epigenetic silencing of HTATIP2 in glioblastoma contributes to treatment resistance by enhancing nuclear translocation of the DNA repair protein MPG.Mol Oncol. 2023 Sep;17(9):1744-1762. doi: 10.1002/1878-0261.13494. Epub 2023 Aug 9. Mol Oncol. 2023. PMID: 37491696 Free PMC article.
-
EPIC-0307-mediated selective disruption of PRADX-EZH2 interaction and enhancement of temozolomide sensitivity to glioblastoma via inhibiting DNA repair and MGMT.Neuro Oncol. 2023 Nov 2;25(11):1976-1988. doi: 10.1093/neuonc/noad102. Neuro Oncol. 2023. PMID: 37279651 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous